PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Prostate Cancer Screening.

Abstract During the prostate-specific antigen-based prostate cancer (PCa) screening era there has been a 53% decrease in the US PCa mortality rate. Concerns about overdiagnosis and overtreatment combined with misinterpretation of clinical trial data led to a recommendation against PCa screening, resulting in a subsequent reversion to more high-risk disease at diagnosis. Re-evaluation of trial data and increasing acceptance of active surveillance led to a new draft recommendation for shared decision making for men aged 55 to 69 years old. Further consideration is needed for more intensive screening in men with high-risk factors. PCa screening significantly reduces PCa morbidity and mortality.
PMID
Related Publications

Overdiagnosis and overtreatment of prostate cancer.

National evidence on the use of shared decision making in prostate-specific antigen screening.

Early-stage prostate cancer, PSA screening rates decline.

Prostate cancer screening practices in a large, integrated health system: 2007-2014.

Prostate Cancer Screening and the Associated Controversy.

Authors

Mayor MeshTerms

Early Detection of Cancer

Keywords

History of prostate cancer screening

PSA

Prostate

Prostate cancer

Prostate cancer screening

Prostate cancer screening guidelines

Prostate-specific antigen

United States Preventive services Task Force

Journal Title the medical clinics of north america
Publication Year Start




PMID- 29406053
OWN - NLM
STAT- MEDLINE
DCOM- 20180208
LR  - 20180208
IS  - 1557-9859 (Electronic)
IS  - 0025-7125 (Linking)
VI  - 102
IP  - 2
DP  - 2018 Mar
TI  - Prostate Cancer Screening.
PG  - 199-214
LID - S0025-7125(17)30187-6 [pii]
LID - 10.1016/j.mcna.2017.11.001 [doi]
AB  - During the prostate-specific antigen-based prostate cancer (PCa) screening era
      there has been a 53% decrease in the US PCa mortality rate. Concerns about
      overdiagnosis and overtreatment combined with misinterpretation of clinical trial
      data led to a recommendation against PCa screening, resulting in a subsequent
      reversion to more high-risk disease at diagnosis. Re-evaluation of trial data and
      increasing acceptance of active surveillance led to a new draft recommendation
      for shared decision making for men aged 55 to 69 years old. Further consideration
      is needed for more intensive screening in men with high-risk factors. PCa
      screening significantly reduces PCa morbidity and mortality.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Catalona, William J
AU  - Catalona WJ
AD  - Department of Urology, Northwestern University Feinberg School of Medicine, 675
      North Saint Clair Street, Suite 20-150, Chicago, IL 63110, USA. Electronic
      address: [email protected]
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Med Clin North Am
JT  - The Medical clinics of North America
JID - 2985236R
RN  - 0 (Biomarkers, Tumor)
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - AIM
SB  - IM
MH  - Biomarkers, Tumor/blood
MH  - Decision Making
MH  - *Early Detection of Cancer/statistics & numerical data
MH  - Humans
MH  - Male
MH  - Mass Screening/statistics & numerical data
MH  - Medical Overuse
MH  - Patient Participation
MH  - Primary Health Care
MH  - Prostate-Specific Antigen/*blood
MH  - Prostatic Neoplasms/blood/*diagnosis/epidemiology
MH  - United States/epidemiology
OTO - NOTNLM
OT  - History of prostate cancer screening
OT  - PSA
OT  - Prostate
OT  - Prostate cancer
OT  - Prostate cancer screening
OT  - Prostate cancer screening guidelines
OT  - Prostate-specific antigen
OT  - United States Preventive services Task Force
EDAT- 2018/02/07 06:00
MHDA- 2018/02/09 06:00
CRDT- 2018/02/07 06:00
PHST- 2018/02/07 06:00 [entrez]
PHST- 2018/02/07 06:00 [pubmed]
PHST- 2018/02/09 06:00 [medline]
AID - S0025-7125(17)30187-6 [pii]
AID - 10.1016/j.mcna.2017.11.001 [doi]
PST - ppublish
SO  - Med Clin North Am. 2018 Mar;102(2):199-214. doi: 10.1016/j.mcna.2017.11.001.